Krystal Biotech, Inc. (1KRYS)
XMIL 
Summary
1KRYS Chart
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
Krystal Biotech Q2 Earnings Call Highlights
Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.
Krystal Biotech, Inc. (1KRYS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Krystal Biotech, Inc. ever had a stock split?
Krystal Biotech, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Krish S. Krishnan CEO | XMIL Exchange | US5011471027 ISIN |
| US Country | 295 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Krystal Biotech, Inc. is a commercial-stage biotechnology company committed to discovering, developing, and delivering genetic medicines for patients with rare diseases in the United States. Since its establishment in 2016, the company has made significant progress in its mission, leveraging cutting-edge technology to address unmet medical needs. Krystal Biotech is based in Pittsburgh, Pennsylvania, where it continues to push the boundaries of genetic medicine to improve patient outcomes in rare disease communities.
Products and Services
Krystal Biotech, Inc. offers a variety of products and services designed to treat rare diseases through innovative genetic medicine approaches. The company's portfolio includes commercialized treatments and products in various stages of clinical development:
- VYJUVEK (beremagene geperpavec-svdt, or B-VEC): This is the company's flagship product, commercially available for treating dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder characterized by fragile skin that easily blisters and tears. Krystal’s approach offers hope for effective management of this debilitating condition.
- KB105: Currently in Phase 1/2 clinical trials, KB105 targets the treatment of patients with deficient autosomal recessive congenital ichthyosis (ARCI), a condition that influences skin appearance and function. The therapy aims to correct the underlying genetic cause of the disease.
- KB104: Aimed at addressing Netherton syndrome, another rare genetic disorder affecting the skin, hair, and immune system, KB104 is under development to potentially provide a novel treatment option for patients suffering from this challenging condition.
- KB407: In Phase 1 clinical trials, KB407 is being developed for the treatment of cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system. This gene therapy seeks to provide a significant improvement in the quality of life for patients with cystic fibrosis.
- KB707: Also in Phase 1 clinical trials, KB707 is designed for the treatment of patients who have relapsed or are refractory to anti-PD-1 therapies. This innovative approach represents a new frontier in cancer treatment, aiming to overcome resistance to current therapies.
- KB408: Targeted towards treating Alpha-1 antitrypsin deficiency, which can result in serious lung diseases, KB408 is another promising therapy in Phase 1 clinical trials. By addressing the genetic root of the disease, Krystal Biotech aims to offer a transformative treatment option.
- KB301: Currently in Phase 2 clinical trials, KB301 is being developed for aesthetic skin conditions. This represents a diversification of Krystal’s portfolio into treatments that can improve the quality of life through cosmetic enhancements. Additionally, an open label study is exploring B-VEC's potential for treating ocular complications of deb, indicating the versatility and broad applicability of the company’s gene therapy platform.
